Northstar Asset Management Stake in Celgene (CELG) Has Decreased by $966,680; Seabridge Investment Advisors Raised Gilead Sciences (GILD) Holding by $766,303

April 17, 2018 - By Ellis Scott

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Northstar Asset Management Llc decreased its stake in Celgene Corporation (CELG) by 43.8% based on its latest 2017Q4 regulatory filing with the SEC. Northstar Asset Management Llc sold 9,295 shares as the company’s stock declined 19.30% with the market. The institutional investor held 11,925 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.25M, down from 21,220 at the end of the previous reported quarter. Northstar Asset Management Llc who had been investing in Celgene Corporation for a number of months, seems to be less bullish one the $69.01 billion market cap company. The stock increased 1.33% or $1.2 during the last trading session, reaching $91.74. About 1.88M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since April 17, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Seabridge Investment Advisors Llc increased its stake in Gilead Sciences Inc. (GILD) by 56.01% based on its latest 2017Q4 regulatory filing with the SEC. Seabridge Investment Advisors Llc bought 10,793 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 30,063 shares of the health care company at the end of 2017Q4, valued at $2.15 million, up from 19,270 at the end of the previous reported quarter. Seabridge Investment Advisors Llc who had been investing in Gilead Sciences Inc. for a number of months, seems to be bullish on the $98.64 billion market cap company. The stock increased 1.29% or $0.96 during the last trading session, reaching $75.65. About 1.93 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 17, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Wednesday, October 4 with “Buy”. On Tuesday, January 16 the stock rating was upgraded by Wells Fargo to “Outperform”. BMO Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, January 2. BMO Capital Markets has “Hold” rating and $86.0 target. The firm earned “Buy” rating on Friday, February 12 by Maxim Group. The stock has “Hold” rating by Oppenheimer on Wednesday, October 4. The firm has “Neutral” rating given on Wednesday, February 8 by Citigroup. The rating was maintained by Leerink Swann with “Market Perform” on Thursday, October 19. The rating was downgraded by Needham on Tuesday, July 26 to “Hold”. Morgan Stanley maintained it with “Equal-Weight” rating and $84 target in Wednesday, February 7 report. The firm earned “Outperform” rating on Friday, February 5 by Leerink Swann.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It is negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Chemical Retail Bank holds 0.23% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 29,143 shares. Private Advisor Grp Inc holds 0.11% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 35,891 shares. Notis holds 15,197 shares. Security Natl Tru Co invested in 0.66% or 28,433 shares. Fosun Ltd stated it has 123,759 shares. Argent has invested 0.67% in Gilead Sciences, Inc. (NASDAQ:GILD). Somerset Commerce stated it has 0.66% in Gilead Sciences, Inc. (NASDAQ:GILD). The Ontario – Canada-based Mackenzie Fincl has invested 0.13% in Gilead Sciences, Inc. (NASDAQ:GILD). Jnba Advisors has 0.12% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Montag A & Associates owns 60,119 shares. Rhode Island-based Amica Mutual Ins has invested 0.6% in Gilead Sciences, Inc. (NASDAQ:GILD). Metropolitan Life Ny owns 242,547 shares. Bailard holds 0.17% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 38,082 shares. Oakwood Capital Mngmt Ltd Liability Ca holds 0.63% or 39,830 shares. Domini Impact Ltd Liability Company holds 5.9% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 4,024 shares.

Since January 2, 2018, it had 0 insider purchases, and 17 insider sales for $39.51 million activity. Another trade for 50,000 shares valued at $3.93 million was sold by MARTIN JOHN C. 60,000 shares were sold by WILSON GAYLE E, worth $4.68 million on Friday, February 9. Alton Gregg H sold $1.11M worth of stock or 15,000 shares. Meyers James R had sold 100,000 shares worth $8.02 million. $401,566 worth of stock was sold by Washington Robin L on Wednesday, February 21.

Seabridge Investment Advisors Llc, which manages about $689.24M and $460.05 million US Long portfolio, decreased its stake in Twenty (NASDAQ:FOX) by 10,581 shares to 31,891 shares, valued at $1.09M in 2017Q4, according to the filing. It also reduced its holding in Liberty Interactive Corporatio (NASDAQ:QVCA) by 84,810 shares in the quarter, leaving it with 21,017 shares, and cut its stake in Broadcom Limited.

Among 34 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 1 Sell and 14 Hold. Therefore 56% are positive. Celgene Corporation had 142 analyst reports since July 21, 2015 according to SRatingsIntel. As per Friday, December 4, the company rating was maintained by Wells Fargo. As per Thursday, July 6, the company rating was maintained by Cantor Fitzgerald. As per Tuesday, April 19, the company rating was maintained by Credit Suisse. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by RBC Capital Markets on Tuesday, January 23. On Monday, January 8 the stock rating was maintained by SunTrust with “Buy”. The firm earned “Underweight” rating on Thursday, October 5 by Morgan Stanley. On Thursday, October 19 the stock rating was maintained by RBC Capital Markets with “Buy”. BTIG Research downgraded the shares of CELG in report on Friday, June 30 to “Neutral” rating. As per Thursday, January 7, the company rating was initiated by SunTrust. The firm has “Buy” rating by SunTrust given on Thursday, January 25.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on May, 4 before the open. They expect $1.77 EPS, up 15.69% or $0.24 from last year’s $1.53 per share. CELG’s profit will be $1.33 billion for 12.96 P/E if the $1.77 EPS becomes a reality. After $1.87 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -5.35% negative EPS growth.

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.34, from 1.17 in 2017Q3. It fall, as 156 investors sold CELG shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. Hardman Johnston Glob Advisors Lc has 437,870 shares. Amalgamated Bank reported 102,626 shares. Sg Americas Ltd Liability has 79,501 shares. Oregon-based Oregon Public Employees Retirement Fund has invested 0.19% in Celgene Corporation (NASDAQ:CELG). Clarivest Asset Lc holds 0.46% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 256,813 shares. Moreover, Cahill Inc has 0.11% invested in Celgene Corporation (NASDAQ:CELG) for 2,034 shares. Pictet & Cie (Europe) Sa holds 199,112 shares. Farmers Merchants Inc, a Nebraska-based fund reported 22,860 shares. Jolley Asset Mngmt Ltd has 524 shares for 0.04% of their portfolio. 1,966 are held by Gagnon Secs Limited. Norinchukin Bancorporation The holds 0.26% or 144,361 shares in its portfolio. First Interstate National Bank & Trust owns 2.31% invested in Celgene Corporation (NASDAQ:CELG) for 104,481 shares. Everett Harris And Ca reported 4,120 shares. Affinity Investment Advsrs Lc invested in 81,363 shares or 0.96% of the stock. 56,115 are held by Thompson Invest Inc.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: